Clarifi ASD in the news
Non-invasive and easily administered saliva test
Accelerates the diagnostic process with results in 3 to 6 weeks
Peer-reviewed research and clinically validated
Measures epigenetic molecules in saliva
Is your child eligible for Clarifi ASD?
Clarifi ASD is currently available to children who meet the following eligibility requirements.
Suspicion of autism
For children with a clinical suspicion of autism, such as a positive screen on
Appropriate age range
Must be 18 months through 6 years of age
Meets geographic requirements
Clarifi ASD is currently available in the U.S., excluding New York State
The road to Clarifi ASD
Read about our team’s journey translating a medical discovery into an innovative clinical product.
Rising autism prevalence and
longer wait times for diagnosis
According to the CDC, 1 in 54 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. A biological, diagnostic tool can further inform clinical judgment and substantially improve early identification.
“There has clearly been an increase in prevalence of autism spectrum disorder in our society. Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes and quality of life.”
Vice President – Product Management
Cutting-edge breakthroughs in epigenetic research
Clarifi ASD is not a genetic test. It is the product of scientific advancements in the area of epigenetics; the factors that influence how genes are turned on and off. Our peer-reviewed research discovered that certain RNA molecules that regulate genetic activity and reflect interactions between a patient and their environment, were different in children with autism.
Translating the science into practical solutions
The next step was turning this novel discovery into a clinically available test to help families. To accomplish this, Admera Health, a CLIA-certified Laboratory, developed and validated the Clarifi autism saliva test by incorporating Quadrant Biosciences’ unique bioinformatics platform.
First ever epigenetic
test for autism
Clarifi ASD is beginning to have a positive impact on families. Here is one parent’s perspective on how the saliva test helped her family.
“A test which can separate children who have screened M-CHAT positive into high likelihood of autism or low likelihood of autism could help streamline waitlists and permit earlier diagnosis and enrollment in autism treatment.”
Dr. Daniel Coury MD
Professor of Pediatrics and Psychiatry at College of Medicine at The Ohio State University and the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital
Diagnosis is only the first step
Quadrant Biosciences is proud to support Autism Speaks in providing resources and solutions to individuals and families touched by autism. In your patient account, you will find links to resources such as toolkits, local service provider directories and other helpful information.
Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the lifespan, for the needs of individuals and their families.
We’ve partnered with top
research and support organizations
Quadrant Biosciences is privileged to be aligned with a number of top autism research and support organizations
“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”
Founder and CEO
Clarifi ASD is now available
Get important details in your inbox